New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression
Atopic dermatitis (AD) is one of the most common chronic, inflammatory skin disorders with a complex etiology and a broad spectrum of clinical phenotypes. Despite its high prevalence and effect on the quality of life, safe and effective systemic therapies approved for long-term management of AD are...
Main Author: | |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-06-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/11/2506 |
id |
doaj-b6363fa734344c9bbda72f477e101dc0 |
---|---|
record_format |
Article |
spelling |
doaj-b6363fa734344c9bbda72f477e101dc02021-06-30T23:24:46ZengMDPI AGJournal of Clinical Medicine2077-03832021-06-01102506250610.3390/jcm10112506New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG ExpressionAnna Dębińska01st Department and Clinic of Paediatrics, Allergology and Cardiology, Wroclaw Medical University, Chałubińskiego 2a, 50-368 Wrocław, PolandAtopic dermatitis (AD) is one of the most common chronic, inflammatory skin disorders with a complex etiology and a broad spectrum of clinical phenotypes. Despite its high prevalence and effect on the quality of life, safe and effective systemic therapies approved for long-term management of AD are limited. A better understanding of the pathogenesis of atopic dermatitis in recent years has contributed to the development of new therapeutic approaches that target specific pathophysiological pathways. Skin barrier dysfunction and immunological abnormalities are critical in the pathogenesis of AD. Recently, the importance of the downregulation of epidermal differentiation complex (EDC) molecules caused by external and internal stimuli has been extensively emphasized. The purpose of this review is to discuss the innovations in the therapy of atopic dermatitis, including biologics, small molecule therapies, and other drugs by highlighting regulatory mechanisms of skin barrier-related molecules, such as filaggrin (FLG) as a crucial pathway implicated in AD pathogenesis.https://www.mdpi.com/2077-0383/10/11/2506atopic dermatitisskin barrierfilaggrinbiologicalssmall molecule therapies |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anna Dębińska |
spellingShingle |
Anna Dębińska New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression Journal of Clinical Medicine atopic dermatitis skin barrier filaggrin biologicals small molecule therapies |
author_facet |
Anna Dębińska |
author_sort |
Anna Dębińska |
title |
New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression |
title_short |
New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression |
title_full |
New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression |
title_fullStr |
New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression |
title_full_unstemmed |
New Treatments for Atopic Dermatitis Targeting Skin Barrier Repair via the Regulation of FLG Expression |
title_sort |
new treatments for atopic dermatitis targeting skin barrier repair via the regulation of flg expression |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2021-06-01 |
description |
Atopic dermatitis (AD) is one of the most common chronic, inflammatory skin disorders with a complex etiology and a broad spectrum of clinical phenotypes. Despite its high prevalence and effect on the quality of life, safe and effective systemic therapies approved for long-term management of AD are limited. A better understanding of the pathogenesis of atopic dermatitis in recent years has contributed to the development of new therapeutic approaches that target specific pathophysiological pathways. Skin barrier dysfunction and immunological abnormalities are critical in the pathogenesis of AD. Recently, the importance of the downregulation of epidermal differentiation complex (EDC) molecules caused by external and internal stimuli has been extensively emphasized. The purpose of this review is to discuss the innovations in the therapy of atopic dermatitis, including biologics, small molecule therapies, and other drugs by highlighting regulatory mechanisms of skin barrier-related molecules, such as filaggrin (FLG) as a crucial pathway implicated in AD pathogenesis. |
topic |
atopic dermatitis skin barrier filaggrin biologicals small molecule therapies |
url |
https://www.mdpi.com/2077-0383/10/11/2506 |
work_keys_str_mv |
AT annadebinska newtreatmentsforatopicdermatitistargetingskinbarrierrepairviatheregulationofflgexpression |
_version_ |
1721351482100416512 |